IONIS-FB-LRx is a specific antisense oligonucleotide (ASO) targeting complement factor B (CFB). IONIS-FB-LRx effectively reduces circulating levels of CFB. IONIS-FB-LRx can be used for geographic atrophy (GA) research[1][2].
in vivo
IONIS-FB-Lrx is administered by subcutaneous injection every four weeks and targets CFB’s hepatic expression[2].
References
[1] Dreismann AK, et al. Gene targeting as a therapeutic avenue in diseases mediated by the complement alternative pathway. Immunol Rev. 2022 Nov 12. DOI:10.1111/imr.13149 [2] Mahmoudzadeh R, et al. Emerging treatments for geographic atrophy in age-related macular degeneration. Curr Opin Ophthalmol. 2021 May 1;32(3):294-300. DOI:10.1097/ICU.0000000000000746
